Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01HL140577 | U.S. NIH Grant/Contract | View source | |
| KL2TR002370 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
| National Center for Advancing Translational Sciences (NCATS) | NIH |
Not provided
Not provided
Not provided
Not provided
A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk, with an additional focus on obesity. Specifically, in a valid circadian protocol, the investigators aim to study resting cardiovascular risk markers and the reactivity of circadian rhythms in these risk markers to standardized stressors. It is intended to compare results in lean and obese individuals to determine if there are specific risks across the circadian cycle specific to obesity. Furthermore, using an exploratory approach, the investigators propose to explore impairment in pre/post synaptic function in the cardiac left ventricle.
Overall, these studies will help us answer whether the circadian system predispose individuals to increased CV disease risk - particularly around the vulnerable morning period, and whether these risks differ with obesity. The results will serve as a foundation for clinical trials of appropriately timed dosing of medications targeting aspects of the CV system that increase effectiveness while decreasing side effects, and may have particular relevance to management of CV risk in people with obesity.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Normal Weight | Healthy lean controls [18.5](streamdown:incomplete-link) |
| |
| Overweight | Healthy obese [30≤BMI<40 and waist circumference ≥94/80 (men and women respectively)] Healthy lean controls [18.5](streamdown:incomplete-link) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle | Combination Product | Drugs are used for as part of physiological monitoring and not as interventions, including imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, and 11C-CGP12177). |
| Measure | Description | Time Frame |
|---|---|---|
| Blood Pressure (BP) | Measurements were collected up to 7 times per participant across the circadian cycle under constant conditions across 5 days. Resting BP and Exercise BP data were collected at the beginning of each of 7 wake periods in a supine position and where participants exercised at an intensity equivalent to brisk walking. Salivary melatonin was used to calculate the circadian phase marker using dim light melatonin onset (DLMO). All data were assigned a circadian phase relative to DLMO and binned into 4-hour (or 60-degree) intervals. In the statistical analysis, the weight group refers to normal or overweight, exercise condition refers to seated or exercising on the bike, and circadian phase refers to the center of the circadian bin. This is an observational study. Due to insufficient enrollment and an imbalanced group distribution, we do not have sufficient statistical power to fully interpret these data. The data are valuable as pilot data for future investigations and sample size estimation. | 5 Days |
| Measure | Description | Time Frame |
|---|---|---|
| Coronary Microvascular Blood Flux | Coronary microvascular function, measured as coronary microvascular blood flux using myocardial contrast echocardiography. | 3 days |
| Flow Mediated Dilation (FMD) |
| Measure | Description | Time Frame |
|---|---|---|
| Beta-adrenergic Receptor Density (Exploratory Outcome) | Radiolabeled agonist (11C-CGP12177) to measure beta-adrenergic receptors during PET Imaging. | 5 days. |
| Norepinephrine Reuptake Transport (Exploratory Outcome) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Community sample
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steven A Shea, PhD | Oregon Institute of Occupational Health Sciences | Principal Investigator |
| Jeanne M Link, PhD | OHSU Center for Radiochemistry Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Normal Weight | Healthy lean controls [18.5](streamdown:incomplete-link) |
| FG001 | Overweight | Healthy obese [30≤BMI<40 and waist circumference ≥94/80 (men and women respectively)] Healthy lean controls [18.5](streamdown:incomplete-link) |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Normal Weight | Healthy lean controls [18.5](streamdown:incomplete-link) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Age at screening |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Blood Pressure (BP) | Measurements were collected up to 7 times per participant across the circadian cycle under constant conditions across 5 days. Resting BP and Exercise BP data were collected at the beginning of each of 7 wake periods in a supine position and where participants exercised at an intensity equivalent to brisk walking. Salivary melatonin was used to calculate the circadian phase marker using dim light melatonin onset (DLMO). All data were assigned a circadian phase relative to DLMO and binned into 4-hour (or 60-degree) intervals. In the statistical analysis, the weight group refers to normal or overweight, exercise condition refers to seated or exercising on the bike, and circadian phase refers to the center of the circadian bin. This is an observational study. Due to insufficient enrollment and an imbalanced group distribution, we do not have sufficient statistical power to fully interpret these data. The data are valuable as pilot data for future investigations and sample size estimation. | These data were collected from an oscillometric blood pressure device. | Posted | Mean | Standard Error | mmHg | 5 Days |
|
From enrollment until end of follow-up (1 week after the in-laboratory monitoring)
Participants were monitored by (1) nursing staff at least once every day (vital signs, and psychological well-being), (2) Research staff during physiological monitoring (blood pressure, heart rate and hemoglobin levels); (3) Regular subjective scales (exertion, sleepiness, etc.); and (4) Non-Systematic Assessment: participants encouraged to self-report any issues of physical or psychological discomfort throughout the study and up to one week after leaving the laboratory.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Normal Weight | Healthy lean controls [18.5](streamdown:incomplete-link) |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Intravenous (IV) Discomfort | Surgical and medical procedures | Standard terminology | Systematic Assessment | A subset of participants reported discomfort at the intravenous (IV) site, which necessitated catheter replacement. In addition, localized application of a heat pack was employed to mitigate the discomfort in individual cases, as appropriate. |
For the exploratory aim, the complex circadian PET protocol was operationally challenging and only partially completed. Short tracer half-lives, lack of automation, tight timing, and overnight chemistry variability caused synthesis issues; plus COVID and staff loss constrained execution. Of 895 screened, 16 enrolled, with no complete datasets. Thus, statistical power and interpretation are limited. These data serve as pilot data; future feasibility will require more personnel, and automation.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Steven A Shea | Oregon Institute of Occupational Health Sciences, OHSU | 5034942517 | sheast@ohsu.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 5, 2025 | Dec 8, 2025 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D021081 | Chronobiology Disorders |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D009682 | Magnetic Resonance Spectroscopy |
| C062942 | 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole |
| ID | Term |
|---|---|
| D013057 | Spectrum Analysis |
| D002623 | Chemistry Techniques, Analytical |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
plasma, saliva
|
|
FMD to measure endothelial function.
| 5 days |
| Heart Rate | Heart rate via 2-channel echocardiogram (ECG) | 5 Days |
| Epinephrine | Venous Epinephrine to estimate sympathetic output | 5 days |
| Norepinephrine | Venous Norepinephrine to estimate sympathetic output | 5 days |
| Cortisol | Saliva cortisol to estimate sympathetic output | 5 days |
Radiolabeled meta-hydroxyephedrine (11C-mHED) to measure norepinephrine reuptake during PET Imaging.
| 5 days. |
| BG001 | Overweight | Healthy obese [30≤BMI<40 and waist circumference ≥94/80 (men and women respectively)] Healthy lean controls [18.5](streamdown:incomplete-link) |
| BG002 | Total | Total of all reporting groups |
| Standard Deviation |
| Years |
|
| Sex: Female, Male | Sex recorded at screening | Count of Participants | Participants |
|
| Race (NIH/OMB) | Race recorded at screening | There were 16 participants and the totals match. | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Ethnicity recorded at screening | There were 16 participants, all of them identified as Not Hispanic or Latino | Count of Participants | Participants |
|
| BMI | Mean | Standard Deviation | kg/meter squared |
|
| Description |
|---|
| OG000 | Normal Weight | Healthy lean controls [18.5](streamdown:incomplete-link) |
| OG001 | Overweight | Healthy obese [30≤BMI<40 and waist circumference ≥94/80 (men and women respectively)] Healthy lean controls [18.5](streamdown:incomplete-link) |
|
|
|
| Secondary | Coronary Microvascular Blood Flux | Coronary microvascular function, measured as coronary microvascular blood flux using myocardial contrast echocardiography. | Not Posted | 3 days | Participants |
| Secondary | Flow Mediated Dilation (FMD) | FMD to measure endothelial function. | Not Posted | 5 days | Participants |
| Secondary | Heart Rate | Heart rate via 2-channel echocardiogram (ECG) | Not Posted | 5 Days | Participants |
| Secondary | Epinephrine | Venous Epinephrine to estimate sympathetic output | Not Posted | 5 days | Participants |
| Secondary | Norepinephrine | Venous Norepinephrine to estimate sympathetic output | Not Posted | 5 days | Participants |
| Secondary | Cortisol | Saliva cortisol to estimate sympathetic output | Not Posted | 5 days | Participants |
| Other Pre-specified | Beta-adrenergic Receptor Density (Exploratory Outcome) | Radiolabeled agonist (11C-CGP12177) to measure beta-adrenergic receptors during PET Imaging. | Not Posted | 5 days. | Participants |
| Other Pre-specified | Norepinephrine Reuptake Transport (Exploratory Outcome) | Radiolabeled meta-hydroxyephedrine (11C-mHED) to measure norepinephrine reuptake during PET Imaging. | Not Posted | 5 days. | Participants |
| 0 |
| 12 |
| 0 |
| 12 |
| 5 |
| 12 |
| EG001 | Overweight | Healthy obese [30≤BMI<40 and waist circumference ≥94/80 (men and women respectively)] Healthy lean controls [18.5](streamdown:incomplete-link) | 0 | 5 | 0 | 5 | 3 | 5 |
|
| Regadenoson Infusion Symptoms | Surgical and medical procedures | Standard terminology | Systematic Assessment | Some people experienced varied sensations after Regadenoson infusion including nausea, altered appetite, flushing, racing heart, headache, shortness of breath, chest tightness or fatigue, all expected. One received aminophylline for symptom relief. |
|
| PET Scan Position Discomfort | Surgical and medical procedures | Standard terminology | Systematic Assessment | Two participants experienced brief shoulder discomfort due to arm positioning during the PET scan. |
|
| General Discomforts | General disorders | Standard terminology | Systematic Assessment | During the 5-day lab stay, two participants reported varied discomforts including fatigue, uncomfortable temperature, disturbed sleep, and diarrhea. |
|
| Eye Discomfort | Eye disorders | Standard terminology | Systematic Assessment | A participant reported dry eyes, which resolved with saline eye drops. The participant also reported discomfort from excessive floor-light brightness, which was resolved by moving the viewing angle. |
|
| Emotional Discomfort | Social circumstances | Standard terminology | Systematic Assessment | One participant reported pre-procedural anxiety, with vital signs remaining within normal limits. Another participant experienced emotional discomfort from being away from family during the 5-day lab study. |
|
Not provided
Not provided
| D009750 |
| Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |